Shares of Savara Inc (NASDAQ:SVRA) have earned a consensus rating of “Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $21.17.

Several research firms have weighed in on SVRA. Zacks Investment Research raised Savara from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Thursday, April 11th. BidaskClub raised Savara from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. ValuEngine raised Savara from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $21.00 price objective on shares of Savara in a research report on Monday, April 1st. Finally, Canaccord Genuity set a $22.00 price objective on Savara and gave the stock a “buy” rating in a research report on Monday, March 25th.

In other Savara news, CFO David L. Lowrance sold 7,500 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $9.02, for a total value of $67,650.00. Following the sale, the chief financial officer now directly owns 2,446 shares in the company, valued at $22,062.92. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $9.03, for a total value of $225,750.00. Following the completion of the sale, the insider now owns 184,754 shares in the company, valued at $1,668,328.62. The disclosure for this sale can be found here. In the last three months, insiders sold 42,761 shares of company stock worth $385,749. Insiders own 6.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Simplex Trading LLC raised its stake in shares of Savara by 246.1% in the fourth quarter. Simplex Trading LLC now owns 4,997 shares of the company’s stock valued at $37,000 after buying an additional 3,553 shares during the period. Virtu Financial LLC bought a new stake in shares of Savara in the fourth quarter valued at $82,000. Jane Street Group LLC bought a new stake in shares of Savara in the fourth quarter valued at $93,000. D. E. Shaw & Co. Inc. bought a new stake in shares of Savara in the fourth quarter valued at $111,000. Finally, Alliancebernstein L.P. bought a new stake in shares of Savara in the third quarter valued at $118,000. Hedge funds and other institutional investors own 48.42% of the company’s stock.

SVRA stock traded up $1.05 during midday trading on Tuesday, hitting $10.70. The company’s stock had a trading volume of 1,913,995 shares, compared to its average volume of 169,472. The company has a current ratio of 15.63, a quick ratio of 15.63 and a debt-to-equity ratio of 0.23. Savara has a 1 year low of $6.21 and a 1 year high of $14.06. The stock has a market cap of $383.38 million, a P/E ratio of -8.29 and a beta of 0.86.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.08. As a group, analysts forecast that Savara will post -1.55 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.